MyoGene Bio is a privately held biotechnology company focused on next-generation genetic therapies for Duchenne and other muscle diseases. Its lead program, MyoDys45-55, employs CRISPR-based editing to delete exons 45-55 of the DMD gene, recreating an in-frame variant that produces a highly functional dystrophin protein similar to that seen in mild Becker muscular dystrophy. This single-edit strategy could be applicable to roughly 50% of Duchenne patients and offers the potential for a one-time, permanent correction, unlike traditional gene-replacement approaches whose durability remains uncertain. The company plans to use newly raised funds to compare the functionality of its corrected dystrophin to other variants and to conduct additional safety characterization studies as it moves toward clinical trials. MyoGene has historically relied on non-dilutive grants and patient-advocacy capital to finance its work and intends to leverage the latest commitments to secure further awards. Including the most recent tranche, the company has attracted $1.42 million in total support from patient-advocacy organizations. No commercial revenue or clinical-stage milestones were disclosed in the article.

Total raised

$0M

Funding rounds

2

Latest round

Equity

Latest activity

Nov 2025